Assays for monitoring cellular immune responses to active immunotherapy of cancer

Clinical Cancer Research

Volumn 7, Issue 5, 2001, Pages 1127-1135

  Clay, Timothy M ^a   Hobeika, Amy C ^a   Mosca, Paul J ^a   Lyerly, H Kim ^a,c,d   Morse, Michael A ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Duke University Trent Drive   (United States)

^c Departments of Pediatrics   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ACCURACY; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE RECEPTOR GENE;

CYTOKINES; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ACTIVE; NEOPLASMS; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0034901519     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Use of a skin test assay to determine tumor-specific CD8+ T cell reactivity
2. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
3. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin-2-transfected cancer cells: Outcome of a Phase I study
4. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)
5. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
6. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
7. Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor
8. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization
9. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
10. Delayed cutaneous hypersensitivity to autologous tumor cells in colon cancer patients immunized with an autologous cell: Bacillus Calmette-Guérin vaccine
11. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line
12. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
13. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases
14. Signaling defects in T lymphocytes of patients with malignancy
15. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
16. Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts
17. Phenotypic analysis of antigen-specific T lymphocytes
18. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers
19. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes
20. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
21. Direct isolation, phenotyping, and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood
22. Longitudinal analysis of T-cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire
23. Quantitation of T-cell receptor frequencies by competitive PCR: Generation and evaluation of novel TCR subfamily and clone specific competitors
24. Immunological issues in vaccine trials: T-cell responses
25. Overexpression of the T-cell receptor β-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas
26. T-cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: Tumor-infiltrating lymphocytes overexpress in vivo the TCR β chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone
27. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes
28. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma
29. Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1
30. An automated method for the analysis of T-cell receptor repertoires. Rapid RT-PCR fragment length analysis of the T-cell receptor β chain complementarity-determining region 3
31. A Phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors
32. Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal cancer
33. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem-cell rescue, and immunization with Theratope STn-KLH cancer vaccine
34. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
35. A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens
36. Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay
37. Detection of intracellular cytokines in citrated whole blood or marrow samples by flow cytometry
38. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of γ-interferon-secreting cells
39. Evaluation of the interferon-γ ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood
40. Quantification of antigen specific CD8+ T cells using an ELISPOT assay
41. Decreased rate of progression and induction of tumor-specific immune response by adjuvant immunotherapy in stage IV melanoma
42. Stimulation of CD8+ T-cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine
43. Digital quantification of the enzyme-linked immunospot (ELISPOT)
44. Development of a dual color enzyme-linked immunospot assay for simultaneous detection of murine T helper type 1- and T helper type 2-cells
45. A recombinant vaccinia virus-based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals
46. Lymphocyte responses and cytokines
47. Identification of functional subsets by flow cytometry: Intracellular detection of cytokine expression
48. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: Evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency
49. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry
50. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: Correlation with induction of increased of intracellular interleukin-2 in peripheral blood lymphocytes
51. Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines - A preliminary report
52. High-sensitivity immunofluorescence for detection of the pro- and anti-inflammatory cytokines γ interferon and interleukin-10 on the surface of cytokine-secreting cells
53. Real time quantitative PCR
54. Quantification of cytokine mRNA expression by RT-PCR in samples of previously frozen blood
55. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens
56. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2
57. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
58. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
59. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response
60. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the antimelanoma lytic activity in peripheral blood of patients with a good clinical performance status: A clinical Phase I study
61. Vaccination with IL-12 gene-modified autologous melanoma cells: Preclinical results and a first clinical Phase I study
62. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype
63. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy
64. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers
65. Rapid determination of Epstein-Barr virus-specific CD8(+) T-cell frequencies by flow cytometry
66. Monitoring CD8 T-cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
67. Eradication of established tumors by CD8+ T cell adoptive immunotherapy
68. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop post-transplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cytotoxic T cells
69. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients